Vera Therapeutics Q2 2026 net loss $109.5M; TRUTAKNA approved and launched

Vera Therapeutics, Inc.

Q2 2026 net loss $109.5M ($1.52/share) vs $76.5M ($1.20) in Q2 2025; cash $499.2M at June 30, 2026.
FDA granted accelerated approval for TRUTAKNA in IgAN; first BAFF/APRIL inhibitor; U.S. launch underway.
ORIGIN 3 final efficacy analysis expected Q3 2026; sBLA submission to FDA expected Q4 2026.
Nancy Boman named Chief Regulatory Officer, succeeding William Turner upon his retirement in Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.